COST-UTILITY OF GRANULOCYTE-COLONY STIMULATING FACTORS FOR PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA IN BREAST CANCER PATIENTS IN BELGIUM

被引：0
|
作者：
Somers, L. [1 ]
Malfait, M. [2 ]
Danel, A. [3 ]
机构：
[1] OncoLogX Bvba, Antwerp, Belgium
[2] Amgen Sa Nv, Brussels, Belgium
[3] Amgen Europe GmbH, Zug, Switzerland
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.2139
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A427 / A427
页数：1
相关论文
共 50 条
  • [1] COST-UTILITY OF GRANULOCYTE-COLONY STIMULATING FACTORS (G-CSFS) FOR PRIMARY PROPHYLAXIS (PP) OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (FN) IN BREAST CANCER PATIENTS IN THE NETHERLANDS
    Somers, L.
    Timmer-Bonte, J. N. H.
    Gelderblom, H.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A415 - A415
  • [2] COST-EFFECTIVENESS AND COST-UTILITY OF GRANULOCYTE COLONY-STIMULATING FACTORS IN THE PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (FN) IN BREAST CANCER PATIENTS IN GREECE: A COMPARATIVE ANALYSIS
    Kourlaba, G.
    Palaka, E.
    Papagiannopoulou, V
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A633 - A633
  • [3] NUMBER NEEDED TO TREAT AND COST UTILITY ANALYSIS OF GRANULOCYTE-COLONY STIMULATING FACTORS FOR PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA IN DLBCL PATIENTS IN THE NETHERLANDS
    Lugtenburg, E.
    Levin, M. D.
    Somers, L.
    [J]. HAEMATOLOGICA, 2014, 99 : 698 - 699
  • [4] Febrile neutropenia primary prophylaxis with granulocyte-colony stimulating factors (G-CSF) in breast cancer
    Younis, T.
    Rayson, D.
    Skedgel, C.
    [J]. CANCER RESEARCH, 2013, 73
  • [5] Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Chris Skedgel
    Daniel Rayson
    Tallal Younis
    [J]. Supportive Care in Cancer, 2016, 24 : 387 - 394
  • [6] Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel, Chris
    Rayson, Daniel
    Younis, Tallal
    [J]. SUPPORTIVE CARE IN CANCER, 2016, 24 (01) : 387 - 394
  • [7] A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
    Douglas, Andrea G.
    Schwab, Phil
    Lane, Daniel
    Kennedy, Kenneth
    Slabaugh, S. Lane
    Bowe, Andy
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (12): : 1221 - 1226
  • [8] Prophylaxis of Febrile Neutropenia with granulocyte-colony stimulating factor
    Takamatsu, Yasushi
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 59 - 59
  • [9] Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan
    Tseng, Tzu-Hsuan
    Chiang, Shao-Chin
    Hsu, Jason C.
    Ko, Yu
    [J]. PLOS ONE, 2024, 19 (06):
  • [10] COST-EFFECTIVENESS ANALYSIS OF GRANULOCYTE COLONY-STIMULATING FACTORS FOR THE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA IN PATIENTS WITH BREAST CANCER IN GREECE
    Kourlaba, G.
    Gourzoulidis, G.
    Aravantinos, G.
    Athanasiadis, I
    Lyman, G. H.
    Villa, G.
    Papagiannopoulou, V
    Tritaki, G.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A456 - A456
12345